A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
A phase 3 trial of IGI, 10% in multiple myeloma, run by Takeda, now recruiting.
Overview
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma is a phase 3 interventional study registered as NCT06980480 by Takeda, with 183 participants planned, started 2026-01-14 and due to reach its primary completion in 2028-09-11. Interventions recorded: IGI, 10%.
Setting
A Multicenter, Randomized, Controlled, Open-label, Group-Sequential, Phase 3 Study to Investigate the Efficacy, Safety, and Tolerability of Intravenous Gammagard Liquid (Immune Globulin Infusion, 10%) for Primary Infection Prophylaxis Compared With Secondary Infection Prophylaxis in Adult Subjects With Multiple Myeloma Receiving B-Cell Maturation AntigenxCD3-Directed Bispecific Antibody Therapy
Phase
Phase 3
Sponsor
Takeda
Registry
Enrolled
183
Similar pages
not linked directly; found by shared links- TrialA Study of TAK-788 in Adults With Non-Small Cell Lung Cancer
Shares Takeda and the tag pipeline.
- TrialA Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors
Shares Takeda and the tag pipeline.
- TrialA Study of TAK-505 in Adults With Solid Tumors
Shares Takeda and the tag pipeline.
- TrialA Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Shares Takeda and the tag pipeline.
- TrialHuman BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM
Shares Multiple myeloma and the tag pipeline.
- TrialA Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.
- TrialStudy of ODX (OsteoDex) in Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.
- TrialA Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.